GlassScriptPhysician profile
Travis Dean Archuleta
NPI 1457335010
$908.44
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $99.26 · 2021: $11.92 · 2022: $225 · 2023: $389 · 2024: $76.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.15 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $187.83 | 2023 | Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $140.46 | 2023-2024 | Keytruda |
| Adc Therapeutics America, INC. | $125.00 | 2022 | |
| Stemline Therapeutics INC. | $94.29 | 2019 | |
| Puma Biotechnology, INC. | $59.68 | 2020 | |
| Pfizer INC. | $56.80 | 2022-2023 | |
| Tempus Ai, INC | $53.89 | 2024 | |
| Novocure INC. | $41.04 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $39.58 | 2020 | |
| Daiichi Sankyo INC. | $26.98 | 2022 | |
| Celgene Corporation | $21.99 | 2023 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $19.47 | 2023 | Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $16.51 | 2023 | |
| Tosoh Bioscience, INC. | $13.00 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Archuleta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.